EQS-News 105 0 Kommentare Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care by Viromed with significant growth potential

Für Sie zusammengefasst

Viromed Medical AG signs exclusive agreement with CORIUS Group for Plasma Care
CORIUS Group to use Viromed's cold plasma therapy in 77 locations in Germany
Viromed expects significant growth potential and additional earnings from 2025

EQS-News: Viromed Medical AG / Key word(s): Alliance
Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care by Viromed with significant growth potential

22.04.2024 / 16:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care by Viromed with significant growth potential

Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care by Viromed for their 1,250,000 patients and is establishing Plasma Care by Viromed as the benchmark in Germany. According to market studies, in Germany alone this important cooperation gives around 40 percent of patients with acute and chronic wounds access to the market-leading cold plasma therapy in terms of the number of devices supplied. By using Plasma Care by Viromed as an exclusive treatment method in one of the largest networks for dermatology and phlebology practices in Europe, Viromed Medical AG expects significant growth potential and anticipates an additional earnings contribution of EUR 0.28 to EUR 0.34 per share from the 2025 financial year onwards.

CORIUS Group, according to its own information the largest dermatology and phlebology practice network in Germany, Switzerland, and the Netherlands, will exclusively use cold plasma therapy with Plasma Care by Viromed in its 77 locations with its own practices and clinics in Germany. Viromed Medical AG believes that the use of Plasma Care by Viromed by the CORIUS Group will have a signal effect for wound treatment in Germany, further accelerating the spread of innovative cold plasma therapy.

Uwe Perbandt, CEO of Viromed Medical AG: ”This agreement is a real milestone for the economic success of our company. It also underlines the CORIUS Group's confidence in our Plasma Care by Viromed technology and its importance for the future of wound treatment. Through the exclusive use of our pioneering cold plasma therapy in the facilities of the CORIUS Group with its 1,250,000 patients, Plasma Care by Viromed will play a key role in innovative wound care. We are convinced that other clinics and care facilities will follow the CORIUS Group's example.“

About Viromed Medical AG:

Viromed Medical AG has a broad customer base in the DACH region, including various DAX companies, e.g. Volkswagen and Lufthansa, as well as federal states and various federal ministries, 1,100 hospitals, 7,000 pharmacies, and 17,000 medical practices.

Contact Viromed Medical AG

Uwe Perbandt
CEO
Flensburger Straße 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de

22.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Viromed Medical AG
	Flensburger Straße 18
	25421 Pinneberg
	Germany
Phone:	+49 4101 809960
E-mail:	kontakt@viromed-medical.de
Internet:	https://www.viromed-medical-ag.de/
ISIN:	DE000A3MQR65
WKN:	A3MQR6
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg
EQS News ID:	1886067